107 related articles for article (PubMed ID: 10524407)
21. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison.
Perez CA; Michalski JM; Purdy JA; Wasserman TH; Williams K; Lockett MA
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):629-37. PubMed ID: 10837945
[TBL] [Abstract][Full Text] [Related]
22. Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms.
Lepor H; Theune C
J Urol; 1995 Jul; 154(1):116-8. PubMed ID: 7776406
[TBL] [Abstract][Full Text] [Related]
23. Herbal and vitamin supplement use in a prostate cancer screening population.
Barqawi A; Gamito E; O'Donnell C; Crawford ED
Urology; 2004 Feb; 63(2):288-92. PubMed ID: 14972473
[TBL] [Abstract][Full Text] [Related]
24. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.
Zelefsky MJ; Kelly WK; Scher HI; Lee H; Smart T; Metz E; Schwartz L; Fuks Z; Leibel SA
J Clin Oncol; 2000 May; 18(9):1936-41. PubMed ID: 10784635
[TBL] [Abstract][Full Text] [Related]
25. Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer.
Pinkawa M; Fischedick K; Asadpour B; Gagel B; Piroth MD; Nussen S; Eble MJ
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):83-9. PubMed ID: 17855010
[TBL] [Abstract][Full Text] [Related]
26. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
[TBL] [Abstract][Full Text] [Related]
27. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
28. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial.
Hoffman KE; Skinner H; Pugh TJ; Voong KR; Levy LB; Choi S; Frank SJ; Lee AK; Mahmood U; McGuire SE; Schlembach PJ; Du W; Johnson J; Kudchadker RJ; Kuban DA
Am J Clin Oncol; 2018 Jun; 41(6):558-567. PubMed ID: 27635624
[TBL] [Abstract][Full Text] [Related]
29. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma.
Zelefsky MJ; Cowen D; Fuks Z; Shike M; Burman C; Jackson A; Venkatramen ES; Leibel SA
Cancer; 1999 Jun; 85(11):2460-8. PubMed ID: 10357419
[TBL] [Abstract][Full Text] [Related]
30. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study.
Harsolia A; Vargas C; Yan D; Brabbins D; Lockman D; Liang J; Gustafson G; Vicini F; Martinez A; Kestin LL
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1100-9. PubMed ID: 17967304
[TBL] [Abstract][Full Text] [Related]
31. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
Yeoh EE; Fraser RJ; McGowan RE; Botten RJ; Di Matteo AC; Roos DE; Penniment MG; Borg MF
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):943-55. PubMed ID: 12605972
[TBL] [Abstract][Full Text] [Related]
32. A-blockers for the management of lower urinary tract symptoms in patients with prostate cancer treated with external beam radiotherapy: a randomized controlled study.
Tsirkas K; Zygogianni A; Kougioumtzopoulou A; Kouloulias V; Liakouli Z; Papatsoris A; Georgakopoulos J; Antypas C; Armpillia C; Dellis A
World J Urol; 2021 Jun; 39(6):1805-1813. PubMed ID: 32776244
[TBL] [Abstract][Full Text] [Related]
33. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Djavan B; Marberger M
Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
[TBL] [Abstract][Full Text] [Related]
34. [The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy].
Suzuki Y; Katoh T; Isurugi K; Obara W; Omori S; Goto Y; Fujioka T; Numasato S
Hinyokika Kiyo; 2001 Jan; 47(1):15-21. PubMed ID: 11235215
[TBL] [Abstract][Full Text] [Related]
35. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Tahmatzopoulos A; Kyprianou N
Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
[TBL] [Abstract][Full Text] [Related]
36. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
[TBL] [Abstract][Full Text] [Related]
37. Alpha-adrenoceptor blocking drugs and female urinary incontinence: prevalence and reversibility.
Marshall HJ; Beevers DG
Br J Clin Pharmacol; 1996 Oct; 42(4):507-9. PubMed ID: 8904625
[TBL] [Abstract][Full Text] [Related]
38. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
Keyes M; Miller S; Pickles T; Halperin R; Kwan W; Lapointe V; McKenzie M; Spadinger I; Pai H; Chan EK; Morris WJ
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):570-8. PubMed ID: 25151536
[TBL] [Abstract][Full Text] [Related]
39. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer.
Cheng JC; Schultheiss TE; Nguyen KH; Wong JY
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):351-7. PubMed ID: 18164841
[TBL] [Abstract][Full Text] [Related]
40. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
